News

Bonumose’s Low-Cost Tagatose Process Receives Key Health Agency Approvals; Construction of First Production Facility on Schedule for Spring 2022 Opening

ASR Group – exclusive sales and distribution partner – reports strong customer demand for the unique, rare sugar, accelerating the timeline for a second production plant.
Bonumose, Inc. announces the achievement of regulatory and food application milestones in the United States and Canada for the low-glycemic, rare sugar tagatose, as the company progresses on time and on schedule for the opening of its first commercial production facility in Spring 2022.
“A low-cost tagatose supply is highly sought after by leading, global food companies for a wide variety of applications that meet sugar-reduction targets in confectionery, ready-to-eat cereal, ice cream, yogurt, beverages, meal replacement drinks, cookies, bars and other popular categories,” said Ed Rogers, CEO of Bonumose. “Tagatose’s unique features enable it to meet calorie-reduction targets without compromising taste or texture while working within companies’ existing food production lines.”

Tagatose – a rare sugar that occurs in tiny quantities in some fruits and grains as well as in the cocoa tree – is 92% as sweet as sugar, maintains a clean, no-aftertaste flavor profile as well as provides critical functionality such as bulking, mouthfeel, caramelization, freezing-point depression and low hygroscopicity. Tagatose has a negligible glycemic index (3), 60 percent fewer calories than sucrose and prebiotic, fiber-like benefits by feeding healthy probiotics in the gut.

To date, the obstacle limiting widespread use of tagatose has been its high cost. Bonumose solves the issue through a lower-cost method using non-dairy, plant-based starch, enzymes and a streamlined process that eliminates several complicated steps that inflate the cost of tagatose and allulose for other producers.

The U.S. Food and Drug Administration (FDA) recently approved Bonumose’s unique method. Additionally, Health Canada approved Bonumose’s process, marking the first time tagatose has been approved for sale in Canada. Regulatory submissions are underway and planned in all major markets worldwide.

Bonumose will launch tagatose production and sales in the first half 2022 with ASR Group, the world’s largest cane sugar refiner and marketer. ASR Group is Bonumose’s exclusive distribution partner in the United States, Canada, Mexico and Western Europe. ASR Group’s customers have successfully tested tagatose in formulations to meet reduction targets without sacrificing taste or function.

“Tagatose has performed extremely well for our customers across a wide variety of applications, and they are enthusiastic about having an affordable supply of tagatose available to them soon,” said Jim Kappas, ASR Group’s Vice President of Specialty Ingredients. “Using these insights, we forecast demand may already outstrip the production capacity at Bonumose’s first production plant, and we will likely need to scale up as soon as possible.”

Recent News

07/17/2025

RIVANNA’s next-generation ultrasound guidance platform and AI-driven imaging software receive FDA 510(K) clearance

RIVANNA®, developers of world-first imaging-based medical technologies, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) regarding the Accuro® 3S diagnostic ultrasound system and SpineNav-AI™ image processing software. This clearance authorizes the use of both technologies in United States hospital and clinical settings, providing anatomical guidance during needle or

07/15/2025

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, announced the closing of its best-efforts offering of 1,500,000 shares of its common stock. Each share of common stock was sold at an offering price of $3.82 per share, priced at-the-market under NYSE American rules. Total gross proceeds from the

07/15/2025

Civica Appoints Dave Sehgal as Chief Manufacturing Officer and Supply Chain Officer

Civica announced the appointment of Dave Sehgal, Ph.D. as its new Chief Manufacturing Officer and Supply Chain Officer, effective July 21. In this role, Dr. Sehgal will lead Civica’s manufacturing strategy and operations, reporting directly to Ned McCoy, President and CEO. “We are excited to welcome Dave to our leadership team,” said McCoy. “His deep